Drug name - Vitekta
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7176220 | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(3 years from now) | |
| US7635704 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(4 years from now) | |
| US8981103 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(4 years from now) | |
| CN100375742C | GILEAD SCIENCES INC | 4-Oxo-Quinoline Compound And Use Thereof |
Jan, 2023
(3 months from now) | |
| CN1692101A | GILEAD SCIENCES INC | 4-Oxo-Quinoline Compounds And Their Use As Hiv Integrase Inhibitors |
Jan, 2023
(3 months from now) | |
| CN1956961A | GILEAD SCIENCES INC | Stable Crystal Form Of 4-Oxoquinoline Compound |
May, 2025
(2 years from now) | |
| CN1956961B | GILEAD SCIENCES INC | 4 Compound Of Stable Crystal |
May, 2025
(2 years from now) | |
| IN200401316P4 | GILEAD SCIENCES INC | 4-Oxoquinoline Compound And Use Thereof As Pharmaceutical Agent |
Nov, 2023
(1 year, 1 month from now) | |
| IN245833B | GILEAD SCIENCES INC | 4-Oxoquinoline Compound As Hiv Integrase Inhibitor |
Nov, 2023
(1 year, 1 month from now) | |
| EP1636190B1 | GILEAD SCIENCES INC | Stable Crystal Of 4-Oxoquinoline Compound |
May, 2025
(2 years from now) | |
| EP1636190A1 | GILEAD SCIENCES INC | Stable Crystal Of 4-Oxoquinoline Compound |
May, 2025
(2 years from now) | |
| EP1564210B9 | GILEAD SCIENCES INC | 4-Oxoquinoline Compounds And Utilization Thereof As Hiv Integrase Inhibitors |
May, 2028
(5 years from now) | |
| EP1564210A1 | GILEAD SCIENCES INC | 4-Oxoquinoline Compounds And Utilization Thereof As Hiv Integrase Inhibitors |
May, 2028
(5 years from now) | |
| EP1564210A4 | GILEAD SCIENCES INC | 4-Oxoquinoline Compounds And Utilization Thereof As Hiv Integrase Inhibitors |
May, 2028
(5 years from now) | |
| EP1564210B1 | GILEAD SCIENCES INC | 4-Oxoquinoline Compounds And Utilization Thereof As Hiv Integrase Inhibitors |
May, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7176220
(Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(4 years from now) | |
|
US7635704
(Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(4 years from now) | |
|
US8981103
(Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(4 years from now) | |
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 85MG | TABLET;ORAL | Discontinued |
| 150MG | TABLET;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.